(Reuters) - Celgene Corp said on Monday that its flagship drug Revlimid (lenalidomide) failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use. Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan (rituximab) and chemotherapy. While the Revlimid study delayed progression of the disease, no survival benefit was seen, the company said. The trial was conducted along with the Lymphoma Study Association. Celgene said it will continue to study Revlimid in a variety of lymphomas. 根据路透社报道,新基公司本周一宣布其旗舰级别的重磅药物来那度胺在弥漫大B维持治疗中与安慰剂相比未能延长生存期。在临床研究中尽管来那度胺延缓了疾病的复发,但是病人在生存期上并未获益。因此,新基公司表示将不就此适应症申请额外的批准,但是该公司说将继续研究来那度胺在其它类型淋巴瘤上的应用。
|